hCD40

品系全名

C57BL/6JSmo-Cd40tm1(hCD40) Smoc

目录号

NM-HU-00076

品系状态

胚胎冻存

导出PDF

基因信息

基因名
CD40

品系描述

在C57BL/6遗传背景下,将小鼠內源Cd40 基因胞外区序列全部替换为人源CD40 序列,表达一个人源嵌合CD40 蛋白。
应用领域:肿瘤研究;免疫治疗;药物筛选

验证数据

image.png

Fig 1. Detection of CD40 expression in peripheral blood cells of humanized CD40 mice. The FACS results of peripheral blood cells collected from homozygous humanized CD40 mice and wild-type mice showed that the active expression of humanized CD40 was detected in CD19 positive cells collected from homozygous humanized CD40 mice, and its expression level was similar to that of murine Cd40 expression in wild-type mice.(Completed in collaboration with CrownBio).

image.png

Fig 2. Analysis of human CD40 expression in the spleen by FACS. The homozygous KI animal expresses human CD40 on the CD19+ B cells.

image.png

Fig 3. Representative flow cytometry staining of GC B cells frommesenteric lymph nodes.

image.png

Fig 4. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized CD40 mice. Humanized CD40 mice were inoculated with MC38 colon cancer cells. After the tumors grew to 100 mm3, the animals were randomly assigned into different group (n=8). The results indicated that the antibodies targeting human CD40 showed a very significant antitumor effect (p<0.001). Combination of anti-CD40 and anti-PD-1 is shown more significant anti-Tumor effect. (Cooperation with CrownBio)

image.png

Fig 5. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized CD40 mice. Homozygous humanized CD40 mice were inoculated with MC38 colon cancer cells. The results showed that an anti-human CD40 antibody exerted a very significant anti-tumor effect , demonstrating that the humanized CD40 mice are a good in vivo model for validating the efficacy of antibodies targeting human CD40. Mean volume ± SEM of tumor tissues(A). Mean body weight ± SEM of mice(B).

image.png

Fig 6. Tumor and weight changes over treated with anti-human CD40 antibody.

image.png

Fig 7. Complete blood count (CBC) of anti-human CD40-antibody treated hCD40 mice.

image.png

Fig 8.Blood chemistry of anti-human CD40-antibody treated hCD40 mice.

image.png

Fig 9. Cytokine analysis of anti-human CD40 antibody treated hCD40 mice. 

Cytokine analysis of anti-human CD40 antibody treated MC38 tumor-bearing model of humanized CD40. Anti-human CD40 antibody treatment led to significant increase several cytokines including IL-12(p40), Eotaxin, etc.


发表文献 2篇

1. Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer
发表年份:2024 来源杂志:JOURNAL OF NANOBIOTECHNOLOGY

2. Tumor Cell Nanovaccines Based on Genetically Engineered Antibody-Anchored Membrane
发表年份:2023 来源杂志:ADVANCED MATERIALS

展开

你也可能感兴趣

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

查看

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

查看

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

查看